Table 1 Patient clinical data
From: Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma
Sex/agea | Symptoms at presentation | Survival months | Bx | Rx | Chemotherapy & vaccine | Primary focusb | Secondary focib (months) |
|---|---|---|---|---|---|---|---|
F5 (3) | Headache | 20 | No | 2x | PARP1/2 inh | Pons | R cerebellum (14) |
Anger | Carboplatin& | ||||||
CN 6 | HDAC inh (CED) | ||||||
F10 (9) | Headache | 13.5 | Yes | 2x | K27M vaccine | Pons | R&L cerebellum |
CN 7, 8 | Nivolumab | R&L LVs (9) | |||||
HDAC/PIK3CA inh | |||||||
F12 (11) | Headache | 13 | Yes | 1x | Erlotinib | Pons | R cerebellum |
CN 7, 8 | Bevacizumab | R LV |